BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31239316)

  • 21. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
    Front Immunol; 2021; 12():610042. PubMed ID: 33679747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
    Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
    Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
    Soldevilla MM; Villanueva H; Meraviglia-Crivelli D; Menon AP; Ruiz M; Cebollero J; Villalba M; Moreno B; Lozano T; Llopiz D; Pejenaute Á; Sarobe P; Pastor F
    Mol Ther; 2019 Nov; 27(11):1878-1891. PubMed ID: 31405808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
    Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
    Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNγ-Dependent Tumor Vessel Regression.
    Kurebayashi Y; Olkowski CP; Lane KC; Vasalatiy OV; Xu BC; Okada R; Furusawa A; Choyke PL; Kobayashi H; Sato N
    Cancer Res; 2021 Jun; 81(11):3092-3104. PubMed ID: 33574087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
    J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
    Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
    Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
    Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
    Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
    Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
    Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
    Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
    Ganesan AP; Johansson M; Ruffell B; Yagui-Beltrán A; Lau J; Jablons DM; Coussens LM
    J Immunol; 2013 Aug; 191(4):2009-17. PubMed ID: 23851682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
    Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
    Yoshida K; Okamoto M; Sasaki J; Kuroda C; Ishida H; Ueda K; Ideta H; Kamanaka T; Sobajima A; Takizawa T; Tanaka M; Aoki K; Uemura T; Kato H; Haniu H; Saito N
    BMC Cancer; 2020 Jan; 20(1):25. PubMed ID: 31914969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
    Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
    PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.